Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Journal: Nature medicine
Published: January 29, 2023
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Journal: European urology
Published: November 08, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Journal: European urology oncology
Published: August 24, 2018
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
Journal: JAMA oncology
Published: March 10, 2018
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Journal: The Journal of urology
Published: July 16, 2017
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.
Journal: Health and quality of life outcomes
Published: November 30, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Journal: European urology
Published: May 06, 2016
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 11, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026